Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application

Author: Ghatnekar Ola   Hjalte Frida   Taylor Matthew  

Publisher: Informa Healthcare

ISSN: 0284-186X

Source: Acta Oncologica, Vol.49, Iss.6, 2010-08, pp. : 851-858

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract